



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/SG/2024-25/113

October 30, 2024

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - BIOCON

Dear Sir/Madam,

Subject: Press Release

Please find enclosed the press release dated October 30, 2024, titled “**Biocon Biologics’ Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)**”

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank Verma
Company Secretary and Compliance Officer
Membership No.: ACS 18776

Encl: Press Release

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Biologics' Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)

Bengaluru, Karnataka, India, Oct 30, 2024

“The U.S. Food and Drug Administration (FDA) has classified Biocon Biologics' Drug Substance Facility at Biocon Campus, (Site 1) located in Bengaluru, Karnataka, as Voluntary Action Indicated (VAI).

This relates to the cGMP inspection conducted by the agency between February 20-28, 2024 and pertains to the supply of rh-Insulin (rhl) Drug Substance to the United States.

Biocon Biologics remains committed to global standards of Quality and Compliance.”

– Company Spokesperson